Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04868604
What this trial is testing

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Clarity Pharmaceuticals Ltd 54
Testing effectiveness (Phase 2)Study completedNCT01929655
What this trial is testing

Japanese BAY88-8223 Monotherapy Phase II Study

Who this might be right for
Prostatic Neoplasms
Bayer 49
Not applicableUnknownNCT03786848
What this trial is testing

Personalized Mini-PDX for Metastatic CRPC

Who this might be right for
Prostate Cancer
Tianjin Medical University Second Hospital 15
Testing effectiveness (Phase 2)Study completedNCT01511536
What this trial is testing

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Sanofi 38
Not applicableEnded earlyNCT02491411
What this trial is testing

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaProstate Adenocarcinoma+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 5
Testing effectiveness (Phase 2)Study completedNCT02463799
What this trial is testing

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 36
Not applicableNo Longer AvailableNCT01834209
What this trial is testing

Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Neoplasms
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Study completedNCT00216099
What this trial is testing

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Christopher Sweeney, MBBS 49
Testing effectiveness (Phase 2)Looking for participantsNCT05272709
What this trial is testing

TT-702 in Patients With Advanced Solid Tumours.

Who this might be right for
Advanced Solid Tumors
Cancer Research UK 60
Large-scale testing (Phase 3)Study completedNCT00861614
What this trial is testing

Study of Immunotherapy to Treat Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
Bristol-Myers Squibb 988
Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Early research (Phase 1)WithdrawnNCT03110588
What this trial is testing

Phase I Trial of PACE for Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
University of Alabama at Birmingham
Early research (Phase 1)Ended earlyNCT01510288
What this trial is testing

Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Amsterdam UMC, location VUmc 28
Testing effectiveness (Phase 2)Study completedNCT00560482
What this trial is testing

Efficacy Study of ABR-215050 to Treat Prostate Cancer

Who this might be right for
Prostate Cancer
Active Biotech AB 206
Testing effectiveness (Phase 2)Ended earlyNCT04157088
What this trial is testing

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

Who this might be right for
Prostatic Cancer, Castration-Resistant
Bayer 30
Testing effectiveness (Phase 2)Ended earlyNCT03999515
What this trial is testing

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaDouble-Negative Prostate CarcinomaMetastatic Prostate Carcinoma+4 more
University of Washington 3
Testing effectiveness (Phase 2)Looking for participantsNCT04606446
What this trial is testing

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer 320
Early research (Phase 1)Looking for participantsNCT07540572
What this trial is testing

Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Who this might be right for
ER+, HER 2- Breast CancerNon-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)+1 more
IDEAYA Biosciences 160
Testing effectiveness (Phase 2)Study completedNCT02012296
What this trial is testing

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Who this might be right for
Hormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
University of Chicago 88
Testing effectiveness (Phase 2)Ended earlyNCT00385827
What this trial is testing

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Who this might be right for
Cancer, Prostate
Centocor, Inc. 106
Next Page